Literature DB >> 15196640

Comparative evaluation of cytotoxicity of a glucosamine-TBA conjugate and a chitosan-TBA conjugate.

Davide Guggi1, Nina Langoth, Martin H Hoffer, Michael Wirth, Andreas Bernkop-Schnürch.   

Abstract

D-glucosamine and chitosan were modified by the immobilization of thiol groups utilizing 2-iminothiolane. The toxicity profile of the resulting D-glucosamine-TBA (4-thiobutylamidine) conjugate, of chitosan-TBA conjugate and of the corresponding unmodified controls was evaluated in vitro. On the one hand, the cell membrane damaging effect of 0.025% solutions of the test compounds was investigated via red blood cell lysis test. On the other hand, the cytotoxity of 0.025, 0.25 and 0.5% solutions of the test compounds was evaluated on L-929 mouse fibroblast cells utilizing two different bioassays: the MTT assay (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide), which assess the mitochondrial metabolic activity of the cells, and the BrdU-based enzyme-linked immunosorbent assay, which measures the incorporation in the DNA of 5-bromo-2'-deoxyuridine and consequently the cell proliferation. Results of the red blood cell lysis test showed that both thiolated compounds displayed a lower membrane damaging effect causing a significantly lower haemoglobine release than the unmodified compounds. Data obtained by the MTT assay and the BrdU assay revealed a concentration dependent relative cytotoxicity for all tested compounds. The covalent linkage of the TBA-substructure to D-glucosamine did not cause a significant increase in cytotoxicity, whereas at higher concentrations a slightly enhanced cytotoxic effect was caused by the derivatisation of chitosan. In conclusion, the -TBA derivatives show a comparable toxicity profile to the corresponding unmodified compounds, which should not compromise their future use as save pharmaceutical excipients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196640     DOI: 10.1016/j.ijpharm.2004.03.016

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation.

Authors:  Sumeet Dhaliwal; Subheet Jain; Hardevinder P Singh; A K Tiwary
Journal:  AAPS J       Date:  2008-06-04       Impact factor: 4.009

2.  Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system.

Authors:  Nina Langoth; Hermann Kahlbacher; Gudrun Schöffmann; Ivo Schmerold; Maximilian Schuh; Sonja Franz; Peter Kurka; Andreas Bernkop-Schnürch
Journal:  Pharm Res       Date:  2006-01-19       Impact factor: 4.200

3.  The impact of vehicles on the mucoadhesive properties of orally administrated nanoparticles: a case study with chitosan-4-thiobutylamidine conjugate.

Authors:  Duangkamon Sakloetsakun; Glen Perera; Juliane Hombach; Gioconda Millotti; Andreas Bernkop-Schnürch
Journal:  AAPS PharmSciTech       Date:  2010-07-29       Impact factor: 3.246

4.  Synthesis of thiolated alginate and evaluation of mucoadhesiveness, cytotoxicity and release retardant properties.

Authors:  A B Jindal; M N Wasnik; Hema A Nair
Journal:  Indian J Pharm Sci       Date:  2010-11       Impact factor: 0.975

5.  Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model.

Authors:  Venkatesan Perumal; Shubhadeep Banerjee; Shubasis Das; R K Sen; Mahitosh Mandal
Journal:  Cancer Nanotechnol       Date:  2011-07-13

Review 6.  Thiolated Chitosans: A Multi-talented Class of Polymers for Various Applications.

Authors:  Christoph Federer; Markus Kurpiers; Andreas Bernkop-Schnürch
Journal:  Biomacromolecules       Date:  2020-07-09       Impact factor: 6.988

7.  SBF-1 inhibits contact hypersensitivity in mice through down-regulation of T-cell-mediated responses.

Authors:  Wei Chen; Xianying Fang; Yuan Gao; Ke Shi; Lijun Sun; Biao Yu; Qiong Luo; Qiang Xu
Journal:  BMC Pharmacol Toxicol       Date:  2019-12-21       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.